Zhu Yong-Ming, Lin Liang, Wei Chao, Guo Yi, Qin Yuan, Li Zhong-Sheng, Kent Thomas A, McCoy Claire E, Wang Zhan-Xiang, Ni Yong, Zhou Xian-Yong, Zhang Hui-Ling
Jiangsu Key Laboratory of Neuropsychiatric Diseases and College of Pharmaceutical Sciences, Laboratory of Cerebrovascular Pharmacology, College of Pharmaceutical Science, Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, School of Public Health, Soochow University, 199 Ren-Ai Road, Suzhou, 215123, Jiangsu, China.
The First Affiliated Hospital of Xiamen University, Xiamen, 361001, Fujian, China.
Transl Stroke Res. 2021 Dec;12(6):991-1017. doi: 10.1007/s12975-021-00888-3. Epub 2021 Feb 24.
Necroptosis initiation relies on the receptor-interacting protein 1 kinase (RIP1K). We recently reported that genetic and pharmacological inhibition of RIP1K produces protection against ischemic stroke-induced astrocytic injury. However, the role of RIP1K in ischemic stroke-induced formation of astrogliosis and glial scar remains unknown. Here, in a transient middle cerebral artery occlusion (tMCAO) rat model and an oxygen and glucose deprivation and reoxygenation (OGD/Re)-induced astrocytic injury model, we show that RIP1K was significantly elevated in the reactive astrocytes. Knockdown of RIP1K or delayed administration of RIP1K inhibitor Nec-1 down-regulated the glial scar markers, improved ischemic stroke-induced necrotic morphology and neurologic deficits, and reduced the volume of brain atrophy. Moreover, knockdown of RIP1K attenuated astrocytic cell death and proliferation and promoted neuronal axonal generation in a neuron and astrocyte co-culture system. Both vascular endothelial growth factor D (VEGF-D) and its receptor VEGFR-3 were elevated in the reactive astrocytes; simultaneously, VEGF-D was increased in the medium of astrocytes exposed to OGD/Re. Knockdown of RIP1K down-regulated VEGF-D gene and protein levels in the reactive astrocytes. Treatment with 400 ng/ml recombinant VEGF-D induced the formation of glial scar; conversely, the inhibitor of VEGFR-3 suppressed OGD/Re-induced glial scar formation. RIP3K and MLKL may be involved in glial scar formation. Taken together, these results suggest that RIP1K participates in the formation of astrogliosis and glial scar via impairment of normal astrocyte responses and enhancing the astrocytic VEGF-D/VEGFR-3 signaling pathways. Inhibition of RIP1K promotes the brain functional recovery partially via suppressing the formation of astrogliosis and glial scar.
坏死性凋亡的启动依赖于受体相互作用蛋白1激酶(RIP1K)。我们最近报道,对RIP1K进行基因和药理学抑制可对缺血性脑卒中诱导的星形胶质细胞损伤产生保护作用。然而,RIP1K在缺血性脑卒中诱导的星形胶质细胞增生和胶质瘢痕形成中的作用仍不清楚。在此,在短暂性大脑中动脉闭塞(tMCAO)大鼠模型以及氧糖剥夺和复氧(OGD/Re)诱导的星形胶质细胞损伤模型中,我们发现RIP1K在反应性星形胶质细胞中显著升高。敲低RIP1K或延迟给予RIP1K抑制剂Nec-1可下调胶质瘢痕标志物,改善缺血性脑卒中诱导的坏死形态和神经功能缺损,并减少脑萎缩体积。此外,在神经元和星形胶质细胞共培养系统中,敲低RIP1K可减轻星形胶质细胞死亡和增殖,并促进神经元轴突生成。血管内皮生长因子D(VEGF-D)及其受体VEGFR-3在反应性星形胶质细胞中均升高;同时,暴露于OGD/Re的星形胶质细胞培养基中的VEGF-D增加。敲低RIP1K可下调反应性星形胶质细胞中VEGF-D的基因和蛋白水平。用400 ng/ml重组VEGF-D处理可诱导胶质瘢痕形成;相反,VEGFR-3抑制剂可抑制OGD/Re诱导的胶质瘢痕形成。RIP3K和MLKL可能参与胶质瘢痕形成。综上所述,这些结果表明,RIP1K通过损害正常星形胶质细胞反应并增强星形胶质细胞VEGF-D/VEGFR-3信号通路参与星形胶质细胞增生和胶质瘢痕形成。抑制RIP1K可部分通过抑制星形胶质细胞增生和胶质瘢痕形成促进脑功能恢复。